We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.34B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+42.67%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.8B
AUM Growth
+$411M
Cap. Flow
+$74.4M
Cap. Flow %
4.14%
Top 10 Hldgs %
62.46%
Holding
77
New
29
Increased
3
Reduced
8
Closed
11

Top Buys

1
SPRY icon
ARS Pharmaceuticals
SPRY
+$84.6M
2
STTK icon
Shattuck Labs
STTK
+$79M
3
SLDB icon
Solid Biosciences
SLDB
+$33.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.9M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.9M

Top Sells

1
KURA icon
Kura Oncology
KURA
+$99.6M
2
STRO icon
Sutro Biopharma
STRO
+$50M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$28.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.9M
5
CBIO
Crescent Biopharma
CBIO
+$11.4M

Sector Composition

1 Healthcare 97.02%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
1
Xencor
XNCR
$1.11B
$198M 11.04%
4,547,072
– –
RLAY icon
2
Relay Therapeutics
RLAY
$4.15B
$133M 7.4%
3,200,649
– –
STTK icon
3
Shattuck Labs
STTK
$604M
$129M 7.16%
+2,456,854
New +$79M
SPRY icon
4
ARS Pharmaceuticals
SPRY
$720M
$117M 6.53%
+2,533,635
New +$84.6M
PRTA icon
5
Prothena Corp
PRTA
$446M
$113M 6.3%
9,426,640
– –
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.1B
$105M 5.82%
3,092,218
+450,000
+17% +$12.9M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 5.67%
464,298
– –
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$95.3M 5.3%
2,839,884
– –
ANAB icon
9
AnaptysBio
ANAB
$1.69B
$69.3M 3.86%
3,223,324
– –
SLDB icon
10
Solid Biosciences
SLDB
$924M
$60.5M 3.36%
+531,847
New +$33.6M
KURA icon
11
Kura Oncology
KURA
$997M
$57.9M 3.22%
1,773,037
-2,835,492
-62% -$99.6M
RCUS icon
12
Arcus Biosciences
RCUS
$3.51B
$57M 3.17%
2,195,892
+385,892
+21% +$9.34M
RNAM
13
DELISTED
Avidity Biosciences
RNAM
$53.7M 2.99%
2,103,950
– –
NRIX icon
14
Nurix Therapeutics
NRIX
$2.43B
$50.8M 2.82%
1,544,019
+351,863
+30% +$11.7M
NGNE icon
15
Neurogene
NGNE
$783M
$44M 2.45%
156,135
-37,012
-19% -$9.04M
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$39.2M 2.18%
2,426,685
– –
AKUS
17
DELISTED
Akouos Inc
AKUS
$39.2M 2.18%
1,975,984
– –
AMTI
18
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$35.4M 1.97%
1,150,000
– –
GERN icon
19
Geron
GERN
$898M
$30.1M 1.68%
18,939,925
-290,844
-2% -$530K
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.8M 1.1%
+1,250,001
New +$18.9M
KLRS
21
Kalaris Therapeutics
KLRS
$107M
$17.2M 0.96%
19,435
– –
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.5M 0.75%
+3,421,287
New +$10.3M
ACIU icon
23
AC Immune
ACIU
$243M
$12.5M 0.69%
+2,410,240
New +$12.3M
KRON
24
DELISTED
Kronos Bio
KRON
$11.6M 0.64%
+387,357
New +$12.2M
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.8M 0.6%
+100,000
New +$9.13M
1
2 3 4

Similar funds

G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
BAM
Berkshire Asset Management Wilkes Barre, Pennsylvania $2.33B AUM 19.33% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
NO
Ninety One Cape Town, South Africa $2.33B AUM 92.42% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.33B AUM 20.04% 1-Year Est. Return
MFAM
Motley Fool Asset Management Alexandria, Virginia $2.33B AUM 21.93% 1-Year Est. Return